Abstract
We report a case of autologous hematopoietic recovery with durable leukemic remission after BMT from a phenotypically HLA-identical donor in a 30-year-old male with CML. Graft loss was diagnosed from day 60 post-BMT by VNTR PCR. To assess for the presence of a minor donor-derived T cell population that could exert an anti-leukemic effect, we serially applied a sensitive process of chimerism analysis by fluorescent PCR on sorted T cells. No residual donor T cells could be detected. We also showed retrospectively that a very sensitive method of MRD analysis by real-time quantitative PCR could have permitted prediction of relapse in this case.
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / analysis
-
Biomarkers, Tumor / genetics
-
Bone Marrow / chemistry
-
Bone Marrow / pathology*
-
Bone Marrow Transplantation*
-
Cell Survival
-
Combined Modality Therapy
-
DNA, Neoplasm / genetics
-
Fusion Proteins, bcr-abl / analysis
-
Fusion Proteins, bcr-abl / genetics
-
Graft Survival
-
Humans
-
Hydroxyurea / administration & dosage
-
Interferon-alpha / administration & dosage
-
Karyotyping
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Leukemia, Myeloid, Chronic-Phase / pathology
-
Leukemia, Myeloid, Chronic-Phase / therapy
-
Male
-
Minisatellite Repeats
-
Neoplasm Recurrence, Local / diagnosis
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm, Residual
-
Polymerase Chain Reaction
-
RNA, Messenger / analysis
-
RNA, Messenger / genetics
-
Remission Induction
-
Salvage Therapy
-
Sensitivity and Specificity
-
T-Lymphocyte Subsets / pathology*
-
Transplantation Conditioning
Substances
-
Biomarkers, Tumor
-
DNA, Neoplasm
-
Interferon-alpha
-
RNA, Messenger
-
Fusion Proteins, bcr-abl
-
Hydroxyurea